Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice. I've been holding this for awhile since the last big pop
btw warrants exercise for $10..presently $2.50..INRN$ $14...
2M trading float.
Two human phase II clinical trials to be conducted in 2021.
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
6:00 am ET July 20, 2020 (Globe Newswire) Print
Key Points
-- NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC
-- Two human phase II clinical trials to be conducted in 2021
-- One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis
-- The second trial will focus on ETEC infections
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that the Naval Medical Research Center (NMRC) has received written guidance from the U.S. Food and Drug administration (FDA) in relation to the clinical development pathway of a new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.
The Type B meeting with the FDA discussed the Chemistry, Manufacturing and Controls including the proposed release testing specifications of the product as well as the planned clinical studies evaluating the safety and efficacy of the product which the company is developing to prevent Campylobacter and ETEC mediated moderate to severe diarrhea.
The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1. Following FDA review the agency provided a written response to the non-clinical questions posed in the briefing documentation as well as providing additional guidance and comments to support the planned IND submission.
"This is an important milestone in the development of any new drug for therapeutic evaluation. The information obtained from this review will assist in the development of the IND application and provides a clear roadmap forward for conducting the two planned clinical studies next year," said Dr. Jerry Kanellos, CEO of Immuron Ltd. "The company is also please to inform shareholders that the manufacturing program is proceeding as planned. We have completed the second immunisation campaign and are on schedule to harvest the Hyper-immune colostrum in September this year which will be used to manufacture the drug product that will be used to treat moderate to severe campylobacteriosis and ETEC infections."
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
For more information visit: http://www.immuron.com
https://ml.globenewswire.com/media/5ed25c41-1de8-4543-bba7-e2dc31c11a8e/small/imc-logo-jpg.jpg
Is anybody home at this company? Horrible volume.
Overpay IMRNW$ $2/ea = $12 breakeven..$14 doubles..$16 triples, etc...
Warrants under $2 exercise for $10.. IMRN$ believer/investor ...
I think so..Always money to made as long as it keeps moving the way it has. My average is 2 and change for the half I'm still holding. I'll pick up some more when it settles
I sold all of mine also around 15. But, Bought some more for 10. You think we go back up next week?
* * $IMRN Video Chart 06-19-2020 * *
Link to Video - click here to watch the technical chart video
I'm suggesting it's not, but was treated like one...
Who said it was..not me. I love this stock. I sold half at $15 pre-market
NOT a pump and dump stock.. low floater IMRN$...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
https://finance.yahoo.com/news/immuron-partners-csiro-produce-oral-100010455.html
Everybody banked and ran..legit stock $9..happy to own shares...
Needs a lot more volume. Had 75 million last Tuesday. 3 million today. Declining interest here.
technical trading/fib retrace imo..low sharecount contracts: trading monster IMRN$..
Whoops. Closed in the $8’s
18M shares trading the 4.4M outstanding.. IMRN$...
Hoped I wasn't alone..taking chance IMRN$..buy again under $10...
Same with me... I saw it 3.00 premarket and did nothing
up we go with drug approval with fda, buy now it is cheap at 15.00
* * $IMRN Video Chart 06-09-2020 * *
Link to Video - click here to watch the technical chart video
saw 6.77 during mid day luls. did nothing of coarse.
Good grief...!! <sigh>
Massive dollar volume!
$IMRN $IMRN Trading $16-$20 & $IMRNW warrants trade at $2.50 ?? with a $10 exercise price for 2 more years?? $IMRNW should be $7+ARBITRAGE?? Bullish
$IMRN $IMRN Trading $16-$20 & $IMRNW warrants trade at $2.50 ?? with a $10 exercise price for 2 more years?? $IMRNW should be $7+ARBITRAGE?? Bullish
$IMRN Trading $16-$20 & $IMRNW warrants trade at $2.50 with a $10 exercise price for 2 more years?? $IMRNW should be $7+. Massive ARBITRAGE?? Bullish
Wow, was fortunate enough to grab some before the explosion. Weeeeeeeee!!!!
Adding Immuron (IMRN) $2.57 to Superbug Watchlist.
Prevent Montezuma’s Revenge BEFORE it starts! Immuron’s direct to consumer product Travelan® is a huge hit with international travelers’ with over $1 million of their magic pills being snapped up in the first half of fiscal 2020. North American (x-US) sales were up 98% year over year. Travelers say “it really, really works!”
http://internetstockreview.com/adding-immuron-imrn-2-57-to-superbug-watchlist/
Great news! Look like every companies want a piece of pie. lol::
is this a CV play
or ??
what just happened
IMRN
* * $IMRN Video Chart 10-02-2019 * *
Link to Video - click here to watch the technical chart video
🇺🇸 The US Department of Defense has reported that @ImmuronLtd's $IMC Travelan® product demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia, indicating broad potential for prevention of travellers' diarrhea: https://t.co/gYsp3WYl4K pic.twitter.com/x7uYaIjYs0
— NWR Communications (@NWRcomms) September 4, 2019
* * $IMRN Video Chart 07-16-2019 * *
Link to Video - click here to watch the technical chart video
Looks like it's going to start heading up now .
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
202
|
Created
|
08/16/17
|
Type
|
Free
|
Moderators |
Immuron Reports Neutralizing activity Against SARS-CoV-2
Key Points:
? | Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studies |
? | Immuron’s technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the GI Tract |
Melbourne, Australia, July 21, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that IMM-124E used to manufacture the company’s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.
The cytopathic effect inhibition cell-based assay was established and performed by 360 biolabs, a Melbourne based Contract Research Organization using the SARS-CoV-2 hCoV-19/Australia/VIC01/2020 virus obtained from Melbourne’s Peter Doherty Institute for Infection and Immunity. The in-vitro assessment of the neutralization of SARS-CoV-2 was performed on four production lots of product used to manufacture Travelan® and Protectyn®. The In-vitro susceptibility of the virus to IMM-124E was determined using the quantitative assay which measures virus replication in the presence of increasing concentrations of the product compared to replication in the absence of the product. The effective concentration of IMM-124E was reported as the concentration of the product at which virus replication is inhibited by 50 percent (EC50) or 90 percent (EC90).
All four production lots produced mean EC50 values of 40.5 to 91.9 ug/mL and inhibited viral replication at concentrations which there was no observed cell toxicity. The concentration of IMM-124E at which virus replication was inhibited by 90 percent (EC90) produced mean EC90 values ranging from 48.7 to 155.4 ug/mL for all four lots tested again at concentrations at which there was no observed cell toxicity. A commercially available high protein milk powder product was used as a placebo in the studies and produced EC50 values greater than the observed cellular cytotoxicity concentration of >4800 ug/mL. The control milk powder inhibited viral replication at doses >25,000 ug/mL and more importantly did not inhibit viral replication at doses which it was cytotoxic to cells.
Another major finding made during the study was that cell viability in the presence of IMM-124E was greatly enhanced when compared to placebo. IMM-124E improved cell viability by 180 to 260% relative to controls. These results indicate that IMM-124E at concentrations which inhibited SARS-CoV-2 replication improved cell viability.
The Type B meeting with the FDA discussed the Chemistry, Manufacturing and Controls including the proposed release testing specifications of the product as well as the planned clinical studies evaluating the safety and efficacy of the product which the company is developing to prevent Campylobacter and ETEC mediated moderate to severe diarrhea.
The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1. Following FDA review the agency provided a written response to the non-clinical questions posed in the briefing documentation as well as providing additional guidance and comments to support the planned IND submission.
“This is an important milestone in the development of any new drug for therapeutic evaluation. The information obtained from this review will assist in the development of the IND application and provides a clear roadmap forward for conducting the two planned clinical studies next year,” said Dr. Jerry Kanellos, CEO of Immuron Ltd. “The company is also please to inform shareholders that the manufacturing program is proceeding as planned. We have completed the second immunisation campaign and are on schedule to harvest the Hyper-immune colostrum in September this year which will be used to manufacture the drug product that will be used to treat moderate to severe campylobacteriosis and ETEC infections.”
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
For more information visit: http://www.immuron.com
www.immuron.com
Level 3, 62 Lygon Street,
Carlton South, Victoria
AUSTRALIA 3053
Phone: + 61 (0)3 9824 5254
Facsimile: + 61 (0)3 9822 7735
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |